Ipamorelin Half-Life & Pharmacokinetics — Research Guide (2026)

Research-use only. This guide summarises published pharmacokinetic (PK) data on Ipamorelin for laboratory research and educational reference. Nothing on this page is medical advice or a recommendation for human use.

Ipamorelin is classified as a Selective ghrelin-receptor (GHS-R1a) agonist / GHRP. Its pharmacokinetic profile — serum half-life, time to peak (Tmax), route-of-administration behaviour, clearance pathway and bioavailability — directly shapes how researchers schedule dosing, interpret PD endpoints and design steady-state experiments.

At-a-Glance Pharmacokinetics

| Parameter | Ipamorelin | | --- | --- | | Classification | Selective ghrelin-receptor (GHS-R1a) agonist / GHRP | | Serum half-life | Serum half-life of approximately 2 hours in published human pharmacokinetic data, producing a short, clean GH pulse without prolactin or cortisol elevation. | | Tmax | Tmax of ~15–30 minutes following subcutaneous administration, with peak GH release at ~30–60 minutes post-injection. | | Validated routes | Subcutaneous is the dominant published research route; intravenous bolus has been used in mechanistic GH-release studies. | | Bioavailability | Subcutaneous bioavailability ~70–80% in published PK reports; oral bioavailability is negligible due to peptide degradation. | | Clearance | Renal clearance with minimal hepatic metabolism; no active metabolites of clinical relevance reported. |

Serum Half-Life

Serum half-life of approximately 2 hours in published human pharmacokinetic data, producing a short, clean GH pulse without prolactin or cortisol elevation.

The functional implication is that steady-state PK is reached at approximately 4–5 half-lives. For Ipamorelin, that informs how quickly researchers can expect plasma exposure to stabilise across repeat dosing.

Time to Peak (Tmax)

Tmax of ~15–30 minutes following subcutaneous administration, with peak GH release at ~30–60 minutes post-injection.

Tmax is the parameter that most directly governs acute pharmacodynamic readouts. For GH-axis peptides this dictates blood-sampling timing for stimulated GH; for incretin analogues it shapes the post-prandial glucose challenge window.

Routes of Administration

Subcutaneous is the dominant published research route; intravenous bolus has been used in mechanistic GH-release studies.

Bioavailability across routes: Subcutaneous bioavailability ~70–80% in published PK reports; oral bioavailability is negligible due to peptide degradation.

Clearance & Metabolism

Renal clearance with minimal hepatic metabolism; no active metabolites of clinical relevance reported.

Key Pharmacokinetic Takeaways

• Shortest acting and most selective of the GHRPs — no measurable prolactin, ACTH or cortisol elevation
• Short half-life supports pulsatile dosing patterns that mimic endogenous GH release
• Frequently paired with longer-acting CJC-1295 to extend functional GH-axis stimulation
• Pharmacokinetic profile underpins its use as a reference GHRP in receptor-selectivity studies

Frequently Asked Questions

What is the half-life of Ipamorelin? Serum half-life of approximately 2 hours in published human pharmacokinetic data, producing a short, clean GH pulse without prolactin or cortisol elevation.

How quickly does Ipamorelin reach peak concentration? Tmax of ~15–30 minutes following subcutaneous administration, with peak GH release at ~30–60 minutes post-injection.

Which routes of administration are validated in published research? Subcutaneous is the dominant published research route; intravenous bolus has been used in mechanistic GH-release studies.

Does Ipamorelin accumulate with repeat dosing? Renal clearance with minimal hepatic metabolism; no active metabolites of clinical relevance reported. Steady-state is typically reached at 4–5 half-lives in published multi-dose studies.

Is oral bioavailability meaningful for Ipamorelin? Subcutaneous bioavailability ~70–80% in published PK reports; oral bioavailability is negligible due to peptide degradation.

Related Research

• Reconstitution & storage protocols — see the Ipamorelin reconstitution guide for vial handling that preserves the PK profile described above.
• Dosing protocols research — see the Ipamorelin dosing protocols article for how PK parameters translate into scheduling decisions.
• Mechanism of action — see the Ipamorelin mechanism guide for the receptor-level basis of the PD effects driven by the PK profile.

---

*Sources cited inline are drawn from published preclinical and clinical pharmacokinetic literature. This article is for laboratory research and educational use only and does not constitute medical advice.*